Action Intersect ENT - XENT

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

Premium

Dernier

28,25

Prix Achat

28,16

Prix Vente

28,36

Volume échangé

0,00 Fourchette du Jour 0,00

0,00 Plage de 52 semaines 0,00

Clôture Veille

28,25

Ouverture

Dernière Transaction

Dernière heure de transaction

Volume moyen (3 m)

Volume financier

VWAP

Real-World Evidence Study Demonstrates Intersect ENT’s PROPEL® Sinus Implant Reduces Healthcare Resource Utilization

Data from first-of-its-kind study published in Current Medical Research and Opinion Patients receiving PROPEL® following endoscopic sinus...

Intersect ENT Reports Third Quarter 2021 Financial Results

Intersect ENT, Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care, today...

First Implants of PROPEL® Contour in Patients with Chronic Rhinosinusitis Following Frontal Sinus Surgery in Europe

Intersect ENT®, Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated...

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Intersect ENT, Inc.

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Intersect ENT, Inc. PR Newswire NEW YORK, Aug. 9, 2021 NEW YORK, Aug. 9, 2021...

Intersect ENT Reports Second Quarter 2021 Financial Results

Intersect ENT, Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care, today...

Medtronic to Acquire Intersect ENT

Medtronic to Acquire Intersect ENT Acquisition to Add Innovative Bioabsorbable Drug Release Platform to...

U.S Nationwide Commercial Availability of the VenSure™ Balloon Sinus Dilation System and Cube™ Navigation System Highlight Intersect ENT’s Continued Commitment to Providing Innovative, Solutions for Patients with Chronic Rhinosinusitis

VenSure and Cube Join the Company’s Portfolio of Localized Drug Delivery Creating an Integrated Offering of ENT Technologies to Treat...

Intersect ENT to Report Second Quarter 2021 Financial Results on August 6

Intersect ENT, Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care, today...

Intersect ENT Announces Preliminary Revenue for Second Quarter of 2021 and Closing of $60 Million Term Loan

Intersect ENT, Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care, today...

Intersect ENT Receives CE Mark Approval for PROPEL® Contour for Patients with Chronic Rhinosinusitis Following Frontal Sinus...

Localized steroid-releasing sinus implant designed to maintain sinus opening now available in select EU countries Intersect ENT®, Inc. (Nasdaq:...

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0	0	0	0	0	0	0	CS
26	0	0	0	0	0	0	0	CS
52	0	0	0	0	0	0	0	CS
156	0	0	0	0	0	0	0	CS
260	0	0	0	0	0	0	0	CS

XENT - Frequently Asked Questions (FAQ)

What is the current Intersect ENT share price?

The current share price of Intersect ENT is US$ 28,25

What is the 1 year trading range for Intersect ENT share price?

Intersect ENT has traded in the range of US$ 0,00 to US$ 0,00 during the past year

Volume
% Gagnants
% Perdants

Symbole	Prix	Vol.
PTIXProtagenic Therapeutics Inc	US$ 0,5129 (85,63%)	5,99M
BTOGBit Origin Ltd	US$ 0,4997 (56,50%)	12,3M
SPPLSIMPPLE Ltd	US$ 0,5578 (34,25%)	891,58k
KIDSOrthoPediatrics Corporation	US$ 28,80 (24,41%)	1
TCBPTC BioPharm Holdings PLC	US$ 2,39 (21,32%)	82
SYRESpyre Therapeutics Inc	US$ 11,00 (-38,68%)	3
SPGCSacks Parente Golf Inc	US$ 0,1222 (-35,68%)	2,57M
OPCHOption Care Health Inc	US$ 22,01 (-35,19%)	4
EOLSEvolus Inc	US$ 9,32 (-35,01%)	8
MIRMMirum Pharmaceuticals Inc	US$ 32,01 (-30,40%)	24
BTOGBit Origin Ltd	US$ 0,50 (56,59%)	12,3M
PTIXProtagenic Therapeutics Inc	US$ 0,5133 (85,78%)	6M
SPGCSacks Parente Golf Inc	US$ 0,1222 (-35,68%)	2,57M
SHViShares Short Treasury Bond ETF	US$ 110,125 (0,01%)	1,32M
SPPLSIMPPLE Ltd	US$ 0,5586 (34,44%)	893,24k

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Intersect ENT Inc (XENT)

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

Statistiques et détails clés

XENT Dernières nouvelles

Real-World Evidence Study Demonstrates Intersect ENT’s PROPEL® Sinus Implant Reduces Healthcare Resource Utilization

Intersect ENT Reports Third Quarter 2021 Financial Results

First Implants of PROPEL® Contour in Patients with Chronic Rhinosinusitis Following Frontal Sinus Surgery in Europe

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Intersect ENT, Inc.

Intersect ENT Reports Second Quarter 2021 Financial Results

Medtronic to Acquire Intersect ENT

U.S Nationwide Commercial Availability of the VenSure™ Balloon Sinus Dilation System and Cube™ Navigation System Highlight Intersect ENT’s Continued Commitment to Providing Innovative, Solutions for Patients with Chronic Rhinosinusitis

Intersect ENT to Report Second Quarter 2021 Financial Results on August 6

Intersect ENT Announces Preliminary Revenue for Second Quarter of 2021 and Closing of $60 Million Term Loan

Intersect ENT Receives CE Mark Approval for PROPEL® Contour for Patients with Chronic Rhinosinusitis Following Frontal Sinus...

XENT - Frequently Asked Questions (FAQ)

Moteurs

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0	0	0	0	0	0	0	CS
26	0	0	0	0	0	0	0	CS
52	0	0	0	0	0	0	0	CS
156	0	0	0	0	0	0	0	CS
260	0	0	0	0	0	0	0	CS

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0	0	0	0	0	0	0	CS
26	0	0	0	0	0	0	0	CS
52	0	0	0	0	0	0	0	CS
156	0	0	0	0	0	0	0	CS
260	0	0	0	0	0	0	0	CS

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Intersect ENT Inc (XENT) Cours

Intersect ENT Inc (XENT)

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

Statistiques et détails clés

XENT Dernières nouvelles

Real-World Evidence Study Demonstrates Intersect ENT’s PROPEL® Sinus Implant Reduces Healthcare Resource Utilization

Intersect ENT Reports Third Quarter 2021 Financial Results

First Implants of PROPEL® Contour in Patients with Chronic Rhinosinusitis Following Frontal Sinus Surgery in Europe

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Intersect ENT, Inc.

Intersect ENT Reports Second Quarter 2021 Financial Results

Medtronic to Acquire Intersect ENT

U.S Nationwide Commercial Availability of the VenSure™ Balloon Sinus Dilation System and Cube™ Navigation System Highlight Intersect ENT’s Continued Commitment to Providing Innovative, Solutions for Patients with Chronic Rhinosinusitis

Intersect ENT to Report Second Quarter 2021 Financial Results on August 6

Intersect ENT Announces Preliminary Revenue for Second Quarter of 2021 and Closing of $60 Million Term Loan

Intersect ENT Receives CE Mark Approval for PROPEL® Contour for Patients with Chronic Rhinosinusitis Following Frontal Sinus...

XENT - Frequently Asked Questions (FAQ)

Moteurs

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Supprimer les publicités

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0	0	0	0	0	0	0	CS
26	0	0	0	0	0	0	0	CS
52	0	0	0	0	0	0	0	CS
156	0	0	0	0	0	0	0	CS
260	0	0	0	0	0	0	0	CS